Human synuclein, alpha (non A4 component of amyloid precursor) oligomer (SNCA oligomer) ELISA kit

Code CSB-E18033h
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details


CUSABIO’s Human synuclein, alpha (non-A4 component of amyloid precursor) oligomer (SNCA oligomer) ELISA kit is designed to quantitatively detect the SNCA content in human serum and plasma. It employs the sandwich ELISA mechanism and enzyme-substrate chromogenic reaction. The forming Ag-Ab-Ag complex is labeled by HRP and reacts with the TMA substrate, making the solution chromogenic. The color intensity is positively related to the amount of SNCA bound in the initial step and can be measured by a microplate reader at 450 nm. This kit performs well in important characteristics, including sensitivity, specificity, precision, recovery, linearity, and lot-ti-lot consistency.

SNCA oligomer is generated by the aggregation of the synuclein-α protein from its soluble monomer into a soluble oligomeric state during the formation of amyloid fibrils. The oligomeric SNCA leads to abnormal free radical production and neuronal toxicity. Mounting evidence showed that SNCA oligomer plays a causative role in the pathogenic etiology of a range of devastating neurodegenerative orders such as Parkinson’s disease (PD) and a series of related synucleinopathies. The quantification of SNCA oligomer holds great potential as a biomarker for those diseases above mentioned.

Target Name synuclein, alpha (non A4 component of amyloid precursor)
Alternative Names Alpha synuclein ELISA Kit; Alpha-synuclein ELISA Kit; Alpha-synuclein; isoform NACP140 ELISA Kit; alphaSYN ELISA Kit; MGC105443 ELISA Kit; MGC110988 ELISA Kit; MGC127560 ELISA Kit; MGC64356 ELISA Kit; NACP ELISA Kit; Non A beta component of AD amyloid ELISA Kit; Non A4 component of amyloid ELISA Kit; Non A4 component of amyloid precursor ELISA Kit; Non-A beta component of AD amyloid ELISA Kit; Non-A-beta component of alzheimers disease amyloid ; precursor of ELISA Kit; Non-A4 component of amyloid precursor ELISA Kit; Non-A4 component of amyloid; precursor of ELISA Kit; OTTHUMP00000218549 ELISA Kit; OTTHUMP00000218551 ELISA Kit; OTTHUMP00000218552 ELISA Kit; OTTHUMP00000218553 ELISA Kit; OTTHUMP00000218554 ELISA Kit; PARK 1 ELISA Kit; PARK 4 ELISA Kit; PARK1 ELISA Kit; PARK4 ELISA Kit; Parkinson disease (autosomal dominant; Lewy body) 4 ELISA Kit; Parkinson disease familial 1 ELISA Kit; SNCA ELISA Kit; Snca synuclein ELISA Kit; Snca synuclein; alpha (non A4 component of amyloid precursor) ELISA Kit; SYN ELISA Kit; Synuclein alpha ELISA Kit; Synuclein alpha 140 ELISA Kit; Synuclein; alpha (non A4 component of amyloid precursor) ELISA Kit; SYUA_HUMAN ELISA Kit
Abbreviation SNCA
Uniprot No. P37840
Species Homo sapiens (Human)
Sample Types serum, plasma
Detection Range 0.312 ng/mL-20 ng/mL
Sensitivity 0.078 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Neuroscience
Assay Principle quantitative
Measurement Sandwich
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of human SNCA oligomer in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
1:1Average %87
Range %82-94
1:2Average %92
Range %87-99
1:4Average %96
Range %90-102
1:8Average %102
Range %96-108
The recovery of human SNCA oligomer spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9086-97
EDTA plasma (n=4)9390-96
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
202.368 2.277 2.323 2.161
101.813 1.905 1.859 1.697
51.198 1.164 1.181 1.019
2.50.772 0.801 0.787 0.625
1.250.451 0.434 0.443 0.281
0.6250.328 0.316 0.322 0.160
0.3120.241 0.233 0.237 0.075
00.163 0.161 0.162  
Materials provided
  • A micro ELISA plate --- The 96-well plate has been pre-coated with an anti-human SNCA antibody. This dismountable microplate can be divided into 12 x 8 strip plates.
  • Two vials lyophilized standard ---Dilute a bottle of the standard at dilution series, read the OD values, and then draw a standard curve.
  • One vial Biotin-labeled SNCA antibody (100 x concentrate) (120 μl/bottle) ---Act as the detection antibody.
  • One vial HRP-avidin (100 x concentrate) (120 μl/bottle) ---Bind to the detection antibody and react with the TMB substrate to make the solution chromogenic.
  • One vial Biotin-antibody Diluent (15 ml/bottle) ---Dilute the Biotin-antibody.
  • One vial HRP-avidin Diluent (15 ml/bottle) ---Dilute the HRP-avidin solution.
  • One vial Sample Diluent (50 ml/bottle)---Dilute the sample to an appropriate concentration.
  • One vial Wash Buffer (25 x concentrate) (20 ml/bottle) ---Wash away unbound or free substances.
  • One vial TMB Substrate (10 ml/bottle) ---Act as the chromogenic agent. TMB interacts with HRP, eliciting the solution turns blue.
  • One vial Stop Solution (10 ml/bottle) ---Stop the color reaction. The solution color immediately turns from blue to yellow.
  • Four Adhesive Strips (For 96 wells) --- Cover the microplate when incubation.
  • An instruction manual
Materials not provided
  • A microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
  • An incubator can provide stable incubation conditions up to 37°C±5°C.
  • Centrifuge
  • Vortex
  • Squirt bottle, manifold dispenser, or automated microplate washer
  • Absorbent paper for blotting the microtiter plate
  • 50-300ul multi-channel micropipette
  • Pipette tips
  • Single-channel micropipette with different ranges
  • 100ml and 500ml graduated cylinders
  • Deionized or distilled water
  • Timer
  • Test tubes for dilution
and FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Customer Reviews and Q&A

 Customer Reviews
Average Rating:
4.0 - 1 reviews

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Sample type: Biological fluids(saliva)

Sample species: Human

Review: We have found in our study that the concentration of salivary alpha-synuclein oligomer was significantly decreased in ASD patients than in healthy subjects. Alpha-synuclein oligomer levels mean in the saliva of patients with ASD, was found to be 0.1359±.059 ng/ml than in that of healthy children where its levels mean was 0.336 ± 0.26 ng/ml (p<0.001).

By Anonymous


Can this kit be used in CSF samples?

Thanks for your inquiry!We tested the mentioned sample stated in the manual. We suggest you follow the manual.If you want to test CSF sample,pls do a pretest first if you want to test it.

Target Background

(From Uniprot)
May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.
Gene References into Functions
  1. Results provide evidence of the role of SNCA in opiate dependence PMID: 21309955
  2. The molecular basis and clinical relevance of statistically decreased alphaSyn pathology in schizophrenic brain versus aged controls is unknown and needs further elucidation as will be necessary for its incidence and relevance in chronic affective disorders. PMID: 19198857
  3. Elevated levels of insoluble alpha-Syn seen in brains of patients with Parkinson's and dementia are higher than that of Parkinson brains, for insoluble and insoluble/soluble alpha-Syn, respectively, with a highly significant difference between the two groups. PMID: 20599975
  4. Data suggest that the key molecular scaffold most effective in inhibiting and destabilizing self-assembly by alphaS requires: (i) aromatic elements for binding to the alphaS monomer/oligomer and (ii) vicinal hydroxyl groups present on a single phenyl ring. PMID: 21443877
  5. [review] The role of alpha-syn is summarized in synaptic vesicle recycling, neurotransmitter synthesis and release and synaptic plasticity, as well as the possible relevance between the loss of normal alpha-syn functions in disease conditions. PMID: 21167933
  6. Age-related accumulation of neuromelanin might induce alpha-synuclein over-expression and thereby make dopamine neurons more vulnerable to injuries. PMID: 21461961
  7. alpha-Synuclein function in promoting cell proliferation is associated with its microtubule assembly activity with the functional domain localized in its carboxyl-terminal part. PMID: 21331461
  8. Association ofalpha-synuclein with Rab attachment receptor protein and soluble sensitive factor attachment receptors (SNAREs) highlights a key role for membrane transport defects in alpha-synuclein-mediated pathology. PMID: 21439320
  9. Our result strongly indicates that Parkinson's disease, induced by alpha-SYN mutation, is evoked by deregulation of the AKT-signaling cascade. PMID: 21474915
  10. Genetic mutations in the alpha-synuclein gene can lead to Parkinson's disease, but even in these patients, age-dependent physiological changes or environmental exposures appear to be involved in disease presentation. PMID: 21238487
  11. Our results imply that CSF alpha-synuclein is currently unsuitable as biomarker to differentiate between PD and AP. PMID: 21236518
  12. [review] Presynaptic function is implicated in the function/dysfunction of alpha-synuclein, the first gene shown to contribute to Parkinson's disease (PD), in this review of genetic models of PD. PMID: 20969957
  13. In the Caucasian patient-control series examined, risk for Parkinson disease is influenced by variation in SNCA and tau proteins but not glycogen synthase kinase (GSK)beta3. PMID: 21159074
  14. Overexpression of alpha-Syn transgene alters dopamine efflux and dopamine D2 receptor modulation of corticostriatal glutamate release at a young age in mice. PMID: 21488084
  15. An artificial microRNA-embedded human SNCA silencing vector is expressed lacks toxicity in rat PC12 cells in which rat SNCA is not silenced and has reduced toxicity in human SH-SY5Y cells in which hSNCA is silenced. PMID: 21338582
  16. Patients with multiple system atrophy may have a cerebrospinal fluid environment particularly favorable for alpha-synuclein fibril formation. PMID: 21215793
  17. Iron up-regulates alpha-synuclein and induces aggregation through the predicted iron responsive element (IRE) in the 5'-untranslated region (UTR) of human alpha-synuclein mRNA. PMID: 20383623
  18. an association of the two SNPs in 4q22/SNCA with the age of onset of Parkinson's disease PMID: 21044948
  19. Findings suggest that alpha-synuclein pathology is associated with Tar DNA-binding protein-43 accumulation in Lewy body disease. PMID: 20669025
  20. Attenuation of nigral SNCA pathology and dopaminergic neurodegeneration by inhibition of NADPH oxidase and iNOS supports a causative relation between inflammation-mediated SNCA pathologic alterations and chronic dopaminergic neurodegeneration. PMID: 21245015
  21. Data describe spontaneous accumulation of hyperphosphorylated tau in striata of a mouse model of Parkinsonism, which overexpresses human a-Synuclein under the PDGF promoter. PMID: 21453448
  22. Direct replication of single nucleotide polymorphisms (SNPs) within SNCA and BST1 confirmed these two genes to be associated with the Parkinson's Disease in the Netherlands. PMID: 21248740
  23. Transgenic alpha-synuclein localizes to the mitochondrial membranes under conditions of proteasomal inhibitory stress; this localization coincides with selective age-related mitochondrial complex I inhibition. PMID: 20887775
  24. Synphilin-1 inhibits alpha-synuclein degradation by the proteasome. PMID: 21103907
  25. From crystal structures of fusions between maltose-binding protein and four segments of alpha-synuclein, the study traces a virtual model of the first 72 residues of alpha -synuclein. PMID: 21462277
  26. In transgenic mice, the norepinephrine systems may be more vulnerable than dopamine systems to toxic effects of aberrant alpha-synuclein; this is in line with the major damage to the noradrenaline system that occurs in patients with Parkinson's disease. PMID: 19152986
  27. In patients diagnosed with dementia with Lewy bodies, lower cerebrospinal fluid alpha-synuclein levels may perhaps be associated with lower cognitive performance, in comparison to patients who are diagnosed with Alzheimer's disease. PMID: 20847452
  28. A novel function for BAG5 as a modulator of CHIP E3 ubiquitin ligase activity with implications for CHIP-mediated regulation of alpha-syn oligomerization. PMID: 21358815
  29. Single-nucleotide polymorphisms in SNCA (rs356219; P = 5.5 x 10(-4) ) is significantly associated with Parkinson's disease PMID: 21425343
  30. alpha-Synuclein thus exerts a primary and direct effect on the morphology of an organelle long implicated in the pathogenesis of Parkinson disease. PMID: 21489994
  31. evidence that alpha-synuclein is a cellular ferrireductase, responsible for reducing iron (III) to bio available iron (II) PMID: 21249223
  32. study found a significant association between the NACP-Rep1 length polymorphism and Beck Depression Inventory (BDI) score; analysis revealed no further association between the In4 polymorphism or between the mRNA expression of SNCA and the BDI score PMID: 21271299
  33. mechanistic insights on the role alpha-synuclein in modulating neurodegenerative phenotypes by regulation of Akt-mediated cell survival signaling in vivo PMID: 21304957
  34. overexpression of alpha-syn may cause mitochondrial defects in dopaminergic neurons of the substantia nigra through an association with adenylate translocator and activation of mitochondria-dependent cell death pathways PMID: 21310263
  35. data demonstrate an elevated state of tauopathy in striata of the A53T alpha-Syn mutant mice, suggesting that tauopathy is a common feature of synucleinopathies PMID: 21445308
  36. REVIEW: alpha-Synuclein in Parkinson disease and other neurodegenerative disorders PMID: 21342025
  37. Data suggest that membrane lipid modification in oligodendroglial cells containing SUMO-1 promotes the formation of alpha-synuclein inclusion bodies resembling protein aggregates in neurodegenerative disease. PMID: 20725866
  38. Data suggest that low SMN levels are associated with significantly lower alpha-synuclein expression, and that alpha-synuclein may be a genetic modifier or biomarker of spinal muscular atrophy. PMID: 20640532
  39. SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes PMID: 21412942
  40. Ubiquitin ligase parkin promotes Mdm2-arrestin interaction but inhibits arrestin ubiquitination PMID: 21466165
  41. analysis of the mechanism of membrane permeabilization by oligomeric alpha-synuclein PMID: 21179192
  42. the relation between membrane physical properties and AS binding affinity and dynamics that presumably define protein localization in vivo and, thereby, the role of AS in the physiopathology of Parkinson disease. PMID: 21330368
  43. MMP3 digestion of alpha-synuclein in DA neurons plays a pivotal role in the progression of Parkinson disease through modulation of alpha-synuclein in aggregation, Lewy body formation, and neurotoxicity PMID: 21330369
  44. Coordination features and affinity of the Cu(2)+ site in the alpha-synuclein protein of Parkinson's disease PMID: 21319811
  45. This study confirms the association between PD and both SNCA SNPs and the H1 MAPT haplotype. PMID: 21391235
  46. In this work Cu(ii) coordination to peptide fragments encompassing residues 45-55 of synuclein alpha has been exhaustively characterized, including systems containing the inherited mutations E46K and A53T, as model peptides of the His-50 site. PMID: 21212878
  47. results support the hypothesis that WT and A53T alpha-synuclein has an important role in the initiation and maintenance of inflammation in Parkinson's disease PMID: 21255620
  48. The combined data indicate that the A30P mutation does not cause changes in the number, location and overall arrangement of beta-strands in amyloid fibrils of alpha-synuclein. PMID: 21280130
  49. Data suggest that mutations in alpha-synuclein may impair specific functional domains, leaving others intact. PMID: 21272100
  50. Single locus analysis showed that G/G SNCA and H1/H1 MAPT risk genotypes were over-represented in patients with Parkinson disease compared with controls PMID: 21054681

Show More

Hide All

Involvement in disease Parkinson disease 1, autosomal dominant (PARK1); Parkinson disease 4, autosomal dominant (PARK4); Dementia Lewy body (DLB)
Subcellular Location Cytoplasm, cytosol, Membrane, Nucleus, Cell junction, synapse, Secreted
Protein Families Synuclein family
Tissue Specificity Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals.
Database Links

HGNC: 11138

OMIM: 127750

KEGG: hsa:6622

STRING: 9606.ENSP00000338345

UniGene: Hs.21374


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2021 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1